Skip to search formSkip to main contentSkip to account menu

IPI-926

Known as: FIN-5, IP9 Free Base, Smoothened Antagonist IPI-926 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Veratrum Alkaloids

Narrower (1)

saridegib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models
Background The Hedgehog pathway receptor smoothened (SMO) has critical roles in tumor progression. However, whether SMO is a key… 
2013
2013
The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway
Abstract 1. IPI-926 is a novel semisynthetic cyclopamine derivative that is a potent and selective Smoothened inhibitor that… 
2012
2012
A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.
213 Background: IPI-926 is a novel, natural product-derived small molecule that targets the Hedgehog (Hh) pathway by inhibiting… 
2012
2012
Antifibrotic therapy in pancreatic diseases
In the current study by Ishiwatari et al , a novel antifibrotic therapy has been shown to revert pancreatic fibrosis induced by… 
2011
2011
The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer.
4114 Background: IPI-926 is a novel, selective, oral, natural product-derived small molecule that targets the Hedgehog (Hh… 
2011
2011
A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
3014 Background: IPI-926 is a novel, selective, oral, natural- product derived small molecule that targets the Hedgehog (Hh… 
2011
2011
Abstract LB-380: Direct targeting of the Hedgehog pathway in primary chondrosarcoma xenografts with the Smoothened inhibitor IPI-926
Chondrosarcoma is a malignant cartilage tumor in which there is constitutive activation of Hedgehog-mediated signaling… 
Review
2011
Review
2011
Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
There are urgent needs to develop novel and more effective regimens to improve outcomes of pancreatic cancer given its dismal… 
2010
2010
Abstract 5045: The Hh inhibitor IPI-926 inhibits relapse of a non-small cell lung cancer xenograft model following treatment with an EGF-R targeted tyrosine kinase inhibitor
The Hedgehog (Hh) pathway plays a key role in multiple types of cancer, either by mutational activation of the pathway in tumor… 
2008
2008
Depilation induced anagen as a model to study hedgehog pathway antagonist IPI-926: Implications for biomarker development
2827 The Hedgehog cell signaling pathway is normally active during embryonic development and plays a critical role in controlling… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)